An observational study in Alzheimer's Disease and Healthy Controls, sponsored by McGill University. Recruiting at 5 sites in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by McGill University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 321 studies in Alzheimer Disease with a site in Canada — 60 open to participants now, 81 under way, 23 of them phase 3. Alzheimer Disease · Canada.
Among the 321 studies in Alzheimer Disease with a site in Canada, this one is the 27th largest by planned enrollment of the 39 observational ones that give a count, is one of 15 that started in 2026, is one of 39 observational ones, reaches primary completion later than 38 of the 80 other live ones, and was the 235th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.
Browse Alzheimer Disease studies →60 of the 321 studies in Alzheimer Disease with a site in Canada are open now. Recruiting first, the newest first:
Hoffmann-La Roche · Sites in Canada, United States, Argentina and 7 more countries
Ages 55–80
Eisai Limited · Sites in Canada
Sanofi · Sites in Canada, United States, Australia and 4 more countries
Ages 55–85
McMaster University · Sites in Canada
Ages 55+
Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal · Sites in Canada
Ages 50–80 · Healthy volunteers
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
321 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 99 · Phase 3 117 · Phase 4 4
First in 1999; this study’s year is marked. 15 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 250 is above the median of 200 across 817 observational studies indexed under Alzheimer Disease.
Median enrollment 241 across the 281 interventional studies, 500 across the 39 observational. Of the 224 that completed or were terminated, 104 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
196 of 321 have an industry lead sponsor. The 10 most frequent:
McGill University is the lead sponsor of 249 studies on the registry; 50 are open to participants now.
McGill University has 2 studies filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
17 of the studies in Alzheimer Disease with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT05543681IGC Pharma, LLCClinical Trial on Agitation in Alzheimer's Dementia | 2026-11 |
| NCT06529744University Health Network, TorontoImproving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling | 2026-11 |
Add all 17 to your calendar (.ics) → With an account.
Among the 321 studies in Alzheimer Disease with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application.
This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by Alzheimer's Disease and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of Alzheimer's Disease and associated cognitive changes.
The criteria were revised on the registry on Oct 14, 2026. See what changed
For this study, we will recruit 250 participants. 125 will be AD patients (including predominant AD with mixed vascular and MCI due to AD), and 125 will be age-matched healthy cognitively intact control participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For all participants:
For patients only:
Exclusion Criteria:
For AD participants:
For all participants:
For healthy controls only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
125 participants will be AD patients (including predominant AD with mixed vascular and MCI due to AD)
Device: Eye-Tracking
125 Participant with no evidence or history of significant neurodegenerative disorder affecting brain function.
Device: Eye-Tracking
Eye-tracking technology and algorithms used to successfully capture and track eye movements using an electronic tablet and the embedded camera of the device.
Clinical Dementia Rating (CDR) score, one time, at the day of enrollment.
The Clinical Dementia Rating (CDR) is a global rating scale for staging patients diagnosed with Alzheimer disease and other dementias and monitoring changes in the level of there disabilities over time. The CDR scale is a 0-3 point numeric scale (0.5 unit increments) derived from clinician rating of cognition and daily function in the domains of memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care.
Time frame: Baseline
The Montreal Cognitive Assessment (MoCA) score, one time, at the day of enrollment.
The Montreal Cognitive Assessment (MoCA) is a brief 30-question cognitive screening test designed to assist Health Professionals in the detection of mild cognitive impairment and Alzheimer's disease. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. Scores on the MoCA range from zero to 30, with a score of 26 and higher generally considered normal.
Time frame: Baseline
The Mini-Mental State Exam (MMSE) score, one time, at the day of enrollment.
The Mini-Mental State Exam (MMSE) is a widely used test of cognitive function among the elderly, it includes tests of orientation, attention, memory, language and visual-spatial skills. It consists of a series of questions and tests that can be used by clinicians to help diagnose dementia and to help assess its progression and severity.
Time frame: Baseline
Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Apr 2022 → May 2026, primary completion Mar 2024 → Nov 2027 and completion Mar 2024 → Nov 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.